218900-56-2

Basic information

• Product Name: TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE
• Synonyms: TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE
• CAS NO: 218900-56-2
• Molecular Formula: C₁₄H₂₁NO₃
• Molecular Weight: 251.32144
• Mol File: 218900-56-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE(218900-56-2)
• EPA Substance Registry System: TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE(218900-56-2)

Safety Data

• Hazardous Substances Data: 218900-56-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE is used as a key intermediate in the synthesis of potential drug candidates due to its carbamate functional group, which can be further modified or reacted to yield bioactive molecules with therapeutic potential.
Used in Research:
TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE is used as a building block in organic chemistry reactions, allowing researchers to explore its reactivity and develop novel synthetic routes to complex organic molecules.
Used in Structure-Activity Relationship Studies:
TERT-BUTYL [(1S)-1-(3-METHOXYPHENYL)ETHYL]CARBAMATE is used as a valuable tool for investigating the structure-activity relationships of different pharmaceutical targets, providing insights into the design of more effective and selective drugs.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 50919-07-8 (S)-1-(3-methoxyphenyl)ethylamine 

Downstream Products

• 63720-38-7 3-hydroxy-(S)-α-phenethylamine 
• 266369-42-0 (S)-[1-(3-hydroxyphenyl)ethyl]carbamic acid tert-butyl ester 
• 477312-35-9 (S)-[1-(3-morpholin-4-yl-phenyl)ethyl]-carbamic acid tert-butyl ester 
• 477312-33-7 (S)-trifluoromethanesulfonic acid 3-(1-tert-butoxycarbonylamino-ethyl)-phenyl ester 
• 889443-69-0 S-(-)-[1-(3-methoxyphenyl)ethyl]-N,N-dimethylamine 
• 139306-10-8 (S)-3-(1-dimethylaminoethyl)phenol 

Relevant articles and documents

Group-assisted Purification (GAP) Chemistry/Technology in synthesizing the chiral intermediate of rivastigmine and its ?-Alkyl benzylamine analogues

Introduction of (S)-configuration is the key step in the synthesis of the anti-dementia drug Rivastigmine. Twenty-one alkylation products were obtained through simple washing with hexane/ethyl acetate (v/v: 10/1) in good yields (>85%) and high diastereoselectivity (up to >99:1 dr). Moreover, the chiral auxiliary could be easily dissociated and readily regenerated. That is, the synthesis was proved to follow group-assisted purification (GAP) chemistry/technology. In addition, the chiral amine produced by this asymmetric alkylation reaction was effectively used in the synthesis of Rivastigmine.

Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl) ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain

Acrylamide (S)-6, a potent and efficacious KCNQ2 (Kv7.2) opener, demonstrated significant activity in two models of neuropathic pain and in the formalin test, suggesting that KCNQ2 openers may be useful in the treatment of neuropathic pain including diabetic neuropathy.

NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA

The invention provides a compound of formula (I), wherein R1, R2 and R3 are as defined in the specification, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers

A new class of acrylamides was synthesized, and the effects of these analogues on outward potassium current were evaluated by using two electrode voltage clamp recordings from Xenopus laevis oocytes expressing cloned mKCNQ2 channels. SAR studies indicated that the pharmacophore of the acrylamide series includes the (S) absolute configuration at the (1-phenyl)ethyl moiety and the α,β-unsaturated acrylamide functionality with a free NH. This study identified (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide ((S)-1) and (S)-N-[1-(4-fluoro-3-morpholin-4-yl-phenyl)-ethyl]-3- (4-fluoro-phenyl)-acrylamide ((S)-2) as KCNQ2 openers for further electrophysiological evaluations. These two acrylamides demonstrated significant activity in the cortical spreading depression model of migraine as we reported previously.